{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T15:28:49Z","timestamp":1792510129974,"version":"4.5.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2023,4,13]],"date-time":"2023-04-13T00:00:00Z","timestamp":1681344000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,4,13]],"date-time":"2023-04-13T00:00:00Z","timestamp":1681344000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Oncol Rep"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1007\/s11912-023-01413-5","type":"journal-article","created":{"date-parts":[[2023,4,13]],"date-time":"2023-04-13T08:02:48Z","timestamp":1681372968000},"page":"825-831","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Aromatase Inhibitor Musculoskeletal Syndrome and Bone Loss: a Review of the Current Literature"],"prefix":"10.1007","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7488-7287","authenticated-orcid":false,"given":"Sara","family":"Christensen Holz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,4,13]]},"reference":[{"issue":"10001","key":"1413_CR1","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1016\/S0140-6736(15)61074-1","volume":"386","author":"Early Breast Cancer Trialists' Collaborative Group (EBCTCG)","year":"2015","unstructured":"Early Breast Cancer Trialists\u2019 Collaborative Group (EBCTCG). Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomized trials. Lancet. 2015;386(10001):1341\u201352.","journal-title":"Lancet"},{"key":"1413_CR2","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1007\/s10549-018-05086-8","volume":"174","author":"X Xu","year":"2019","unstructured":"Xu X, Chlebowski RT, Shi J, Barac A, Haque R. Aromatase inhibitor and tamoxifen use and the risk of venous thromboembolism in breast cancer survivors. Breast Cancer Res Treat. 2019;174:785\u201394.","journal-title":"Breast Cancer Res Treat"},{"issue":"3","key":"1413_CR3","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1007\/s10549-018-4713-2","volume":"169","author":"LI Wagner","year":"2018","unstructured":"Wagner LI, Zhao F, Goss PE, Chapman JW, Shepherd LE, Whelan TJ, Mattar BI, Bufill JA, Schultz WC, LaFrancis IE, Nagargoje GG, Vemuri R, Nikcevich DA, Sledge GW, Cella D. Patient-reported predictors of early treatment discontinuation: treatment-related symptoms and health-related quality of life among postmenopausal women with primary breast cancer randomized to anastrozole or exemestane on NCIC. Clinical Trials Group Breast Cancer Res Treat. 2018;169(3):537.","journal-title":"Clinical Trials Group Breast Cancer Res Treat"},{"issue":"10","key":"1413_CR4","doi-asserted-by":"publisher","first-page":"775","DOI":"10.3816\/CBC.2007.n.038","volume":"7","author":"CA Presant","year":"2007","unstructured":"Presant CA, Bosserman L, Young T, Vakil M, Horns R, Upadhyaya G, Ebrahimi B, Yeon C, Howard F. Aromatase inhibitor-associated arthralgia and\/ or bone pain: frequency and characterization in non-clinical trial patients. Clin Breast Cancer. 2007;7(10):775\u20138.","journal-title":"Clin Breast Cancer"},{"issue":"9","key":"1413_CR5","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1200\/JCO.2011.38.0261","volume":"30","author":"NL Henry","year":"2012","unstructured":"Henry NL, Azzouz F, Desta Z, Li L, Nguyen AT, Lemler S, Hayden J, Tarpinian K, Yakim E, Flockhart DA, Stearns V, Hayes DF, Storniolo AM. Predictors of aromatase inhibitor discontinuation as a result of treatment-emergent symptoms in early-stage breast cancer. AM J Clin Oncol. 2012;30(9):936\u201342.","journal-title":"AM J Clin Oncol."},{"issue":"16","key":"1413_CR6","doi-asserted-by":"publisher","first-page":"5625","DOI":"10.3390\/ijms21165625","volume":"21","author":"S Tenti","year":"2020","unstructured":"\u2022 Tenti S, Correale P, Cheleschi S, Fioravanti A, Pirtoli L. Aromatase inhibitors-induced musculoskeletal disorders: current knowledge on clinical and molecular aspects. Int J Mol Sci. 2020;21(16):5625. This study has an up to date review on aromatase inhibitors effect on musculoskeletal syndromes and current understanding of mechanisms.","journal-title":"Int J Mol Sci"},{"issue":"12","key":"1413_CR7","doi-asserted-by":"publisher","first-page":"713700","DOI":"10.3389\/fendo.2021.713700","volume":"27","author":"T Hyder","year":"2021","unstructured":"\u2022 Hyder T, Marino CC, Ahmad S, Nasrazadani A, Brufsky AM. Aromatase inhibitor-associated musculoskeletal syndrome: understanding mechanisms and management. Front Endocrinol (Lausanne). 2021;27(12):713700. This article discusses proposed criteria for aromatase inhibitor arthralgia and gives a good overview of the current knowledge of the condition.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"6","key":"1413_CR8","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1093\/annonc\/mdt037","volume":"24","author":"P Niravath","year":"2013","unstructured":"Niravath P. Aromatase inhibitor-induced arthralgia: a review. Ann Oncol. 2013;24(6):1443\u20139.","journal-title":"Ann Oncol"},{"key":"1413_CR9","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1007\/s10549-010-0757-7","volume":"120","author":"O Din","year":"2010","unstructured":"Din O, Dodwell D, Wakefield R, et al. Aromatase inhibitor induced arthralgia in early breast cancer: what do we know and how can we find out more? Breast Cancer Res Treat. 2010;120:525\u201338.","journal-title":"Breast Cancer Res Treat"},{"key":"1413_CR10","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s10549-006-9394-6","volume":"104","author":"L Morales","year":"2007","unstructured":"Morales L, Pans S, Paridaens R, et al. Debilitating musculoskeletal pain and stiffness with letrozole and exemestane: associated tenosynovial changes on magnetic resonance imaging. Breast Cancer Res Treat. 2007;104:87\u201391.","journal-title":"Breast Cancer Res Treat"},{"key":"1413_CR11","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1177\/039463201102400430","volume":"24","author":"V Bruzzese","year":"2011","unstructured":"Bruzzese V, Hassan C, Zullo A, Zampa G. Rheumatoid arthritis: a complication of aromatase inhibitor therapy? Int J Immunopathol Pharmacol. 2011;24:1099\u2013101.","journal-title":"Int J Immunopathol. Pharmacol."},{"key":"1413_CR12","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.jbspin.2010.05.016","volume":"78","author":"E Bertolini","year":"2011","unstructured":"Bertolini E, Letho-Gyselinck H, Prati C, Wendling D. Rheumatoid arthritis and aromatase inhibitors. Jt Bone Spine. 2011;78:62\u20134.","journal-title":"Jt Bone Spine"},{"key":"1413_CR13","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.3899\/jrheum.080648","volume":"36","author":"J Chao","year":"2009","unstructured":"Chao J, Parker BA, Zvaifler NJ. Accelerated cutaneous nodulosis associated with aromatase inhibitor therapy in a patient with rheumatoid arthritis. J Rheumatol. 2009;36:1087\u20138.","journal-title":"J Rheumatol"},{"issue":"2","key":"1413_CR14","doi-asserted-by":"publisher","first-page":"e000523","DOI":"10.1136\/rmdopen-2017-000523","volume":"3","author":"M Caprioli","year":"2017","unstructured":"Caprioli M, Carrara G, Sakellariou G, Silvagni E, Scir\u00e8 CA. Influence of aromatase inhibitors therapy on the occurrence of rheumatoid arthritis in women with breast cancer: results from a large population-based study of the Italian Society for Rheumatology. RMD Open. 2017;3(2):e000523.","journal-title":"RMD Open"},{"issue":"9","key":"1413_CR15","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1016\/S1470-2045(08)70182-7","volume":"9","author":"I Sestak","year":"2008","unstructured":"Sestak I, Cuzick J, Sapunar F, Eastell R, Forbes JF, Bianco AR, et al. Risk factors for joint symptoms in patients enrolled in the atac trial: a retrospective, exploratory analysis. Lancet Oncol. 2008;9(9):866\u201372.","journal-title":"Lancet Oncol"},{"key":"1413_CR16","first-page":"73","volume":"8","author":"DA Yardley","year":"2016","unstructured":"Yardley DA. Pharmacologic management of bone-related complications and bone metastases in postmenopausal women with hormone receptorpositive breast cancer. Breast Cancer (Dove Med Press). 2016;8:73\u201382.","journal-title":"Breast Cancer (Dove Med Press)"},{"issue":"16","key":"1413_CR17","doi-asserted-by":"publisher","first-page":"3631","DOI":"10.1002\/cncr.24419","volume":"115","author":"JJ Mao","year":"2009","unstructured":"Mao JJ, Stricker C, Bruner D, Xie S, Bowman MA, Farrar JT, et al. Patterns and risk factors associated with aromatase inhibitor-related arthralgia among breast cancer survivors. Cancer. 2009;115(16):3631\u20139.","journal-title":"Cancer"},{"issue":"7","key":"1413_CR18","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1200\/JCO.2007.11.0726","volume":"26","author":"R Eastell","year":"2008","unstructured":"Eastell R, Adams JE, Coleman RE, Howell A, Hannon RA, Cuzick J, et al. Effect of anastrozole on bone mineral density: 5-year results from the anastrozole, tamoxifen, alone or in combination trial 18233230. J Clin Oncol. 2008;26(7):1051\u20137.","journal-title":"J Clin Oncol"},{"issue":"4","key":"1413_CR19","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1016\/S1470-2045(18)30116-5","volume":"19","author":"S De Placido","year":"2018","unstructured":"De Placido S, Gallo C, De Laurentiis M, Bisagni G, Arpino G, Sarobba MG. Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATAGIM3): a randomised, phase 3 trial. Lancet Oncol. 2018;19(4):474\u201385.","journal-title":"Lancet Oncol"},{"key":"1413_CR20","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1093\/annonc\/mdu103","volume":"25","author":"R Coleman","year":"2014","unstructured":"Coleman R, Body JJ, Aapro M, Hadji P, Herrstedt J. ESMO Guidelines Working Group. Bone health in cancer patients: ESMO clinical practice guidelines. ANN Oncol. 2014;25:124\u201337.","journal-title":"ANN Oncol"},{"key":"1413_CR21","doi-asserted-by":"publisher","first-page":"e1911080","DOI":"10.1001\/jamanetworkopen.2019.11080","volume":"2","author":"R Pedersini","year":"2019","unstructured":"Pedersini R, Amoroso V, Maffezzoni F, Gallo F, Turla A, Monteverdi S, Ardine M, Ravanelli M, Vassalli L, Rodella F, et al. Association of fat body mass with vertebral fractures in postmenopausal women with early breast cancer undergoing adjuvant aromatase inhibitor therapy. JAMA Netw Open. 2019;2:e1911080.","journal-title":"JAMA Netw Open"},{"issue":"3","key":"1413_CR22","doi-asserted-by":"publisher","first-page":"445e","DOI":"10.1097\/PRS.0000000000008835","volume":"149","author":"KY Chung","year":"2022","unstructured":"\u2022 Chung KY, Ho G, Novak CB, Baltzer HL. Aromatase inhibitor-induced carpal tunnel syndrome and stenosing tenosynovitis: a systematic review. Plast Reconstr Surg. 2022;149(3):445e\u201352e. This is the most up to date reference regarding carpal tunnel syndrome associated with aromatase inhibitors.","journal-title":"Plast Reconstr Surg"},{"issue":"5","key":"1413_CR23","doi-asserted-by":"publisher","first-page":"e28786","DOI":"10.1097\/MD.0000000000028786","volume":"101","author":"DJ Shin","year":"2022","unstructured":"Shin DJ, Nam KE, Song DH, Im S, Won SJ, Kim YH, Lim SH, Lee JI. Carpal tunnel syndrome and tenosynovitis in women with breast cancer associated with hormone therapy: a multi-institutional analysis using a clinical data warehouse. Medicine (Baltimore). 2022;101(5):e28786.","journal-title":"Medicine (Baltimore)"},{"issue":"3","key":"1413_CR24","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1007\/s10549-019-05270-4","volume":"176","author":"JY Sheng","year":"2019","unstructured":"Sheng JY, Blackford AL, Bardia A, Venkat R, Rosson G, Giles J, Hayes DF, Jeter SC, Zhang Z, Hayden J, Nguyen A, Storniolo AM, Tarpinian K, Henry NL, Stearns V. Prospective evaluation of finger two-point discrimination and carpal tunnel syndrome among women with breast cancer receiving adjuvant aromatase inhibitor therapy. Breast Cancer Res Treat. 2019;176(3):617\u201324.","journal-title":"Breast Cancer Res Treat"},{"issue":"2","key":"1413_CR25","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1159\/000491874","volume":"11","author":"N Mitsimponas","year":"2018","unstructured":"Mitsimponas N, Klouva E, Tryfonopoulos D, Grivas A, Demiri S, Koumakis G, Gouveris P. Aromatase inhibitor-associated tendinopathy and muscle tendon rupture: report of three cases of this exceedingly rare adverse event. Case Rep Oncol. 2018;11(2):557\u201361.","journal-title":"Case Rep Oncol"},{"issue":"10","key":"1413_CR26","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1093\/rheumatology\/kem213","volume":"46","author":"HA Martens","year":"2007","unstructured":"Martens HA, Schr\u00f6der CP, van der Eerden PJ, Willemse PH, Posthumus MD. Severe disabling tendinopathy caused by anastrazole. Rheumatology (Oxford). 2007;46(10):1619\u201321.","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"1413_CR27","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1007\/s10549-009-0692-7","volume":"120","author":"K Briot","year":"2010","unstructured":"Briot K, Tubiana-Hulin M, Bastit L, Kloos I, Roux C. Effect of a switch of aromatase inhibitors on musculoskeletal symptoms in postmenopausal women with hormone-receptor-positive breast cancer: the (articular tolerance of letrozole) study. Breast Cancer Res Treat. 2010;120(1):127\u201334.","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"1413_CR28","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/S1470-2045(17)30715-5","volume":"19","author":"M Colleoni","year":"2018","unstructured":"Colleoni M, Luo W, Karlsson P, Chirgwin J, Aebi S, Jerusalem G, et al. Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2018;19(1):127\u201338.","journal-title":"Lancet Oncol"},{"issue":"4","key":"1413_CR29","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1007\/s11764-015-0511-6","volume":"10","author":"H Arem","year":"2016","unstructured":"Arem H, Sorkin M, Cartmel B, Fiellin M, Capozza S, Harrigan M, Ercolano E, Zhou Y, Sanft T, Gross C, Schmitz K, Neogi T, Hershman D, Ligibel J, Irwin ML. Exercise adherence in a randomized trial of exercise on aromatase inhibitor arthralgias in breast cancer survivors: the hormones and physical exercise (HOPE) study. J Cancer Surviv. 2016;10(4):654\u201362.","journal-title":"J Cancer Surviv"},{"key":"1413_CR30","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.maturitas.2020.06.022","volume":"141","author":"L Boing","year":"2020","unstructured":"\u2022 Boing L, Vieira MCS, Moratelli J, Bergmann A, Guimar\u00e3es ACA. Effects of exercise on physical outcomes of breast cancer survivors receiving hormone therapy - a systematic review and meta-analysis. Maturitas. 2020;141:71\u201381. This article reviews the most recent review on exercise treatment for aromatase inhibitor musculoskeletal syndrome.","journal-title":"Maturitas"},{"issue":"1","key":"1413_CR31","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s12955-019-1090-4","volume":"17","author":"TRS Paulo","year":"2019","unstructured":"Paulo TRS, Rossi FE, Viezel J, Tosello GT, Seidinger SC, Sim\u00f5es RR, de Freitas R Jr, Freitas IF Jr. The impact of an exercise program on quality of life in older breast cancer survivors undergoing aromatase inhibitor therapy: a randomized controlled trial. Health Qual Life Outcomes. 2019;17(1):17.","journal-title":"Health Qual Life Outcomes."},{"issue":"1","key":"1413_CR32","first-page":"CD013167","volume":"1","author":"KE Roberts","year":"2022","unstructured":"\u2022\u2022\u00a0Roberts KE, Adsett IT, Rickett K, Conroy SM, Chatfield MD, Woodward NE. Systemic therapies for preventing or treating aromatase inhibitor-induced musculoskeletal symptoms in early breast cancer. Cochrane Database Syst Rev. 2022;1(1):CD013167. The most up to date review of the literature on the prevention and treatment of AIMSS.","journal-title":"Cochrane Database Syst Rev."},{"key":"1413_CR33","doi-asserted-by":"publisher","first-page":"745280","DOI":"10.3389\/fonc.2021.745280","volume":"11","author":"XY Zhu","year":"2021","unstructured":"\u2022 Zhu XY, Li Z, Chen C, Feng RL, Cheng BR, Liu RY, Wang RT, Xu L, Wang Y, Tao X, Zhao P. Physical therapies for psychosomatic symptoms and quality of life induced by aromatase inhibitors in breast cancer patients: a systematic review and meta-analysis. Front Oncol. 2021;11:745280. Another good review of current exercise therapies for AIMSS.","journal-title":"Front Oncol"},{"issue":"6","key":"1413_CR34","first-page":"2331","volume":"32","author":"M Kubo","year":"2012","unstructured":"Kubo M, Onishi H, Kuroki S, Okido M, Shimada K, Yokohata K, et al. Short-term and low-dose prednisolone administration reduces aromatase inhibitor-induced arthralgia in patients with breast cancer. Anticancer Res. 2012;32(6):2331\u20136.","journal-title":"Anticancer Res"},{"issue":"4","key":"1413_CR35","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1200\/JCO.2017.74.6651","volume":"36","author":"NL Henry","year":"2018","unstructured":"Henry NL, Unger JM, Schott AF, Fehrenbacher L, Flynn PJ, Prow DM, Sharer CW, Burton GV, Kuzma CS, Moseley A, Lew DL, Fisch MJ, Moinpour CM, Hershman DL, Wade JL 3rd. Randomized, multicenter, placebo-controlled clinical trial of duloxetine versus placebo for aromatase inhibitor-associated arthralgias in early-stage breast cancer: SWOG S1202. J Clin Oncol. 2018;36(4):326.","journal-title":"J Clin Oncol."},{"issue":"2","key":"1413_CR36","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1001\/jama.2018.8907","volume":"320","author":"DL Hershman","year":"2018","unstructured":"Hershman DL, Unger JM, Greenlee H, Capodice JL, Lew DL, Darke AK, Kengla AT, Melnik MK, Jorgensen CW, Kreisle WH, Minasian LM, Fisch MJ, Henry NL, Crew KD. Effect of acupuncture vs sham acupuncture or waitlist control on joint pain related to aromatase inhibitors among women with early-stage breast cancer: a randomized clinical trial. JAMA. 2018;320(2):167\u201376.","journal-title":"JAMA"},{"issue":"6","key":"1413_CR37","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s11912-019-0795-1","volume":"21","author":"K Anand","year":"2019","unstructured":"Anand K, Niravath P. Acupuncture and Vitamin D for the Management of Aromatase Inhibitor-Induced Arthralgia. Curr Oncol Rep. 2019;21(6):51.","journal-title":"Curr Oncol Rep."},{"key":"1413_CR38","first-page":"603","volume":"172","author":"S Shen","year":"2018","unstructured":"Shen S, Unger JM, Crew KD, Till C, Greenlee H, Gralow J, Dakhil SR, Minasian LM, Wade JL, Fisch MJ, et al. Omega-3 fatty acid use for obese breast cancer patients with aromatase inhibitor-related arthralgia (SWOG S0927) Breast Cancer Res. Treat. 2018;172:603\u201310.","journal-title":"Treat"},{"key":"1413_CR39","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1007\/s10549-017-4559-z","volume":"167","author":"MB Lustberg","year":"2018","unstructured":"Lustberg MB, Orchard TS, Reinbolt R, Andridge R, Pan X, Belury M, Cole R, Logan A, Layman R, Ramaswamy B, et al. Randomized placebo-controlled pilot trial of omega 3 fatty acids for prevention of aromatase inhibitor-induced musculoskeletal pain. Breast Cancer Res Treat. 2018;167:709\u201318.","journal-title":"Breast Cancer Res Treat"},{"key":"1413_CR40","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/s10549-018-4811-1","volume":"171","author":"CA Santa-Maria","year":"2018","unstructured":"Santa-Maria CA, Bardia A, Blackford AL, Snyder C, Connolly RM, Fetting JH, Hayes DF, Jeter SC, Miller RS, Nguyen A, et al. A phase II study evaluating the efficacy of zoledronic acid in prevention of aromatase inhibitor-associated musculoskeletal symptoms: the ZAP trial. Breast Cancer Res Treat. 2018;171:121\u20139.","journal-title":"Breast Cancer Res Treat"}],"container-title":["Current Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-023-01413-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11912-023-01413-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-023-01413-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,9]],"date-time":"2023-06-09T05:14:34Z","timestamp":1686287674000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11912-023-01413-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,13]]},"references-count":40,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["1413"],"URL":"https:\/\/doi.org\/10.1007\/s11912-023-01413-5","relation":{},"ISSN":["1523-3790","1534-6269"],"issn-type":[{"value":"1523-3790","type":"print"},{"value":"1534-6269","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,13]]},"assertion":[{"value":"20 March 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The author declares no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}]}}